Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus SUMYCIN.
MECLAN vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic